Date: 2015-10-21
Type of information: IPO
Company: Cortendo (Sweden)now Strongbridge Biopharma (Ireland)
Investors:
Amount: $25 million
Funding type: IPO
Planned used:
Others: * On October 21, 2015, Strongbridge Biopharma announced the closing of its initial U.S. public offering of 2,500,000 ordinary shares at a price to the public of $10.00 per ordinary share for aggregate gross proceeds of $25 million, before deducting the underwriting commission and estimated offering expenses. In connection with the offering, Strongbridge Biopharma has granted to the underwriters a 30-day option to purchase up to an additional 375,000 ordinary shares at the public offering price, less the underwriting discount. Strongbridge Biopharma's ordinary shares are listed on The NASDAQ Global Select Market under the symbol "SBBP". Stifel acted as the sole book-running manager for the offering. JMP Securities acted as lead manager, and Roth Capital Partners and Arctic Securities acted as co-managers. * On October 16, 2015, Strongbridge Biopharma announced the pricing of its initial U.S. public offering of 2,500,000 ordinary shares at a price to the public of $10 per share, for total gross proceeds of approximately $25 million. In connection with the offering, Strongbridge Biopharma has granted to the underwriters a 30-day option to purchase up to an additional 375,000 ordinary shares at the public offering price, less the underwriting discount. Strongbridge Biopharma's ordinary shares are currently quoted on the NOTC A-list in Norway and are expected to begin trading on The NASDAQ Global Select Market under the symbol "SBBP" on October 16, 2015. On October 14, 2015, the last reported sale price of Strongbridge Biopharma's ordinary shares on the NOTC was NOK 120 per share, equivalent to a price of $14.82 per share, assuming an exchange rate of NOK 8.0982 per U.S. dollar. * On September 21, 2015, Strongbridge Biopharma announced that it has commenced its initial U.S. public offering of 4,250,000 ordinary shares. In connection with this offering, Strongbridge Biopharma expects to grant to the underwriters a 30-day option to purchase up to an additional 637,500 ordinary shares. The ordinary shares are currently quoted on the NOTC, A-list in Norway under the symbol “SBBP,” and Strongbridge Biopharma has applied to list its ordinary shares on The NASDAQ Global Market under the same symbol. * On August 31, 2015, Cortendo announced it has filed a registration statement on Form F-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Cortendo AB has applied to list its ordinary shares on The NASDAQ Global Market under the ticker symbol “SBBP.” BofA Merrill Lynch and Stifel are acting as joint book-running managers of the proposed offering. JMP Securities is acting as lead manager, Roth Capital Partners is acting as co-manager and Arctic Securities is acting as an advisor. The offering will be made only by means of a prospectus.
Therapeutic area:
